Silver Book Fact

Anti-platelet therapy stroke risk reduction

Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.

Antithrombotic Trialists' Collaboration. Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients. BMJ. 2002; 324(7329): 71-86. http://www.bmj.com/content/324/7329/71.full

Reference

Title
Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients
Publication
BMJ
Publication Date
2002
Authors
Antithrombotic Trialists' Collaboration
Volume & Issue
Volume 324, Issue 7329
Pages
71-86
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • According to the Pharmaceutical Research and Manufacturers of America, 146 new medicines are being developed for heart disease and stroke. They include 17 for stroke, 16 for congestive heart failure,…  
  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
  • In the 1980s, approximately 400,000 major infarctions were occurring each year in the U.S. and 40% of patients were dying within the first year. 1-year mortality is now 4-8%.  
  • About 70% of the survival improvement in heart attack mortality resulted from changes in technology.